Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Everest Medicines Limited (1952.HK)
HKD28.94
+1.34 (+4.86%)
CN HKSE Healthcare Biotechnology
Address
Plaza 66 200040
Shanghai, CN
Shanghai, CN
CEO
Yongqing Luo
Website
everestmedicines.com
IPO
2020-10-09
ISIN KYG3224E1061
Description
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD28.94
+1.34 (+4.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
1.50
Float Shares
261.63M
Free Float %
74.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.87% | -4.62% | -12.74% | -20.35% | -36.06% | -18.50% | -31.73% | +163.46% | -59.79% | -58.57% | -58.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
28.94
Ratings Trend (MoM)
43% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | -1 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.84
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+141.5% ★ Q4'25: +211.1% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%+72.5% ★ Q4'25: +88.7% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.8% Q4'25: -16.3% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-20.2% Q4'25: -5.3% (vs Q4'24)
-
ROIC Biotechnology: -16.1%-9.8% ★ Q4'25: -3.8% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+4.8% Q4'25: +7.1% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.38× Q4'25: -303.90× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 6 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
54.0K
est: 132.1K (-59.1%)
|
12.79M
est: 1.94B (-99.3%)
|
125.93M
est: 389.34M (-67.7%)
|
706.68M
est: 704.14M (+0.4%)
|
1.71B
est: 1.76B (-2.9%)
|
3.49B
3.11B – 3.69B
+98.5% YoY
|
4.88B
3.13B – 6.36B
+39.9% YoY
|
6.89B
5.19B – 8.23B
+41.2% YoY
|
| EBITDA |
-972.78M
est: -77.9K (-1,248,781.8%)
|
-198.91M
est: -1.15B (+82.6%)
|
-744.63M
est: -317.07M (-134.8%)
|
-670.04M
est: -573.44M (-16.8%)
|
-211.18M
est: -1.43B (+85.2%)
|
-2.84B
-3.01B – -2.53B
-98.5% YoY
|
-3.97B
-5.18B – -2.55B
-39.9% YoY
|
-5.61B
-6.70B – -4.23B
-41.2% YoY
|
| EBIT |
-1.00B
est: -79.3K (-1,266,478.8%)
|
-241.68M
est: -1.17B (+79.3%)
|
-821.40M
est: -327.16M (-151.1%)
|
-780.21M
est: -591.69M (-31.9%)
|
-343.89M
est: -1.48B (+76.7%)
|
-2.93B
-3.10B – -2.61B
-98.5% YoY
|
-4.10B
-5.34B – -2.63B
-39.9% YoY
|
-5.79B
-6.91B – -4.36B
-41.2% YoY
|
| Net Income |
-1.01B
est: -1.44B (+30.2%)
|
-247.28M
est: -532.18M (+53.5%)
|
-844.46M
est: -979.75M (+13.8%)
|
-1.04B
est: -998.82M (-4.3%)
|
-297.77M
est: -109.79M (-171.2%)
|
174.24M
158.38M – 292.08M
+258.7% YoY
|
590.41M
415.17M – 765.64M
+238.9% YoY
|
1.19B
961.90M – 1.43B
+102.4% YoY
|
| SGA |
440.83M
est: 217.07M (+103.1%)
|
603.23M
est: 3.19T (-100.0%)
|
396.57M
est: 639.72B (-99.9%)
|
758.15M
est: 1.16T (-99.9%)
|
1.06B
est: 2.89T (-100.0%)
|
5.73T
5.11T – 6.07T
+98.5% YoY
|
8.02T
5.14T – 10.44T
+39.9% YoY
|
11.32T
8.53T – 13.52T
+41.2% YoY
|
| EPS |
-3.44
est: -4.50 (+23.6%)
|
-0.83
est: -1.65 (+49.6%)
|
-2.70
est: -3.04 (+11.2%)
|
-3.24
est: -3.07 (-5.4%)
|
-0.89
est: -0.34 (-163.4%)
|
0.69
0.47 – 0.87
+305.1% YoY
|
1.82
1.23 – 2.28
+162.1% YoY
|
3.45
2.86 – 4.24
+89.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
794.61M
OE per share TTM
2.44
Owner's Yield
7.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
120.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 60 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.62% | 400.9K | 0.59% |
| 2 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.10% | 379.4K | 0.47% |
| 3 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.10% | 377.3K | 0.50% |
| 4 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.09% | 442.3K | 0.32% |
| 5 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.08% | 61.4K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.06% | 354.1K | 0.55% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.06% | 201.7K | 0.74% |
| 8 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.06% | 215.7K | 0.72% |
| 9 | State Street SPDR S&P China ETF GXC | 0.03% | 114.5K | 0.59% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 3.58M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-517.1K
Shares Outstanding
351.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian Ying Woo | Chief Financial Officer, President & Executive Director | 17.2K | male |
| Ying Woo | Chief Financial Officer, President & Executive Director | 17.2K | male |
| Yongqing Luo | Chief Executive Officer & Executive Director | 16.8K | male |
| Yifang Wu | Executive Chairman of the Board | 10.5K | male |
| Sandra Zeng | Chief Medical Officer | — | female |
| Chonggang Xu | Chief Operations Officer | — | male |
| Wenjun Liu | Co-President & Chief Commercial Officer | — | male |
| Xu Liang | Chief Product Officer | — | male |
| Yee Wa Lau | Joint Company Secretary | — | female |
| Wei Yang | Chief Scientific Officer | — | — |
| Jason Brown | Chief Business Officer | — | — |
| King Hang Yeung | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1952.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
